Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: J Neurosci Res. 2010 Aug 15;88(11):2398–2408. doi: 10.1002/jnr.22408

Fig. 1.

Fig. 1

Calpeptin reduced clinical symptoms of disease in acute EAE animals. Lewis rats with acute EAE were ip injected twice-daily with calpeptin (250 µg/kg) or vehicle on days 1 to 9 (before onset, red arrow) or on days 7 to 9 post-EAE induction (at onset, green arrow) and monitored for clinical signs of disease until day 15 (n = 8 to 12 rats per group). Clinical scores for EAE-vehicle group significantly increased (P ≤ 0.05) over EAE-calpeptin-before onset and calpeptin-at onset. There was no significant difference between calpeptin treated groups.